Top

31-05-2018 | Psoriatic arthritis | Article

Comparison of US patient, rheumatologist, and dermatologist perceptions of psoriatic disease symptoms: results from the DISCONNECT study

Journal: Arthritis Research & Therapy

Authors: M. Elaine Husni, Anthony Fernandez, Brett Hauber, Rakesh Singh, Joshua Posner, Jessie Sutphin, Arijit Ganguli

Publisher: BioMed Central

Abstract

Background

The perceived bother of skin and joint-related manifestations of psoriatic disease may differ among patients, rheumatologists, and dermatologists. This study identified and compared the patient and dermatologist/rheumatologist-perceived bother of psoriatic disease manifestations.

Methods

Online surveys were administered to patients with both psoriasis and psoriatic arthritis and to dermatologists and rheumatologists. Object-case best–worst scaling was used to identify the most and least bothersome items from a set of five items in a series of questions. Each item set was drawn from 20 items describing psoriatic disease skin and joint symptoms and impacts on daily activities. Survey responses were analyzed using random-parameters logit models for each surveyed group, yielding a relative-bother weight (RBW) for each item compared with joint pain, soreness, or tenderness.

Results

Surveys were completed by 200 patients, 150 dermatologists, and 150 rheumatologists. Patients and physicians agreed that joint pain, soreness, and tenderness are among the most bothersome manifestations of psoriatic disease (RBW 1.00). For patients, painful, inflamed, or broken skin (RBW 1.03) was more bothersome, while both rheumatologists and dermatologists considered painful skin much less bothersome (RBW 0.17 and 0.22, respectively) than joint pain. Relative to joint pain, rheumatologists were more likely to perceive other joint symptoms as bothersome, while dermatologists were more likely to perceive other skin symptoms as bothersome.

Conclusions

This study has identified important areas of discordance both between patients and physicians and between rheumatologists and dermatologists about the relative bother of a comprehensive set of psoriatic disease symptoms and functional impacts. Both physician specialists should ask patients which manifestations of psoriatic disease are most bothersome to them, as these discussions may have important implications for drug and other patient management options.

Lebwohl M, Swensen AR, Nyirady J, Kim E, Gwaltney CJ, Strober BE. The psoriasis symptom diary: development and content validity of a novel patient-reported outcome instrument. Int J Dermatol. 2014;53:714–22.CrossRefPubMed

National Psoriasis Foundation. About psoriatic arthritis. https://www.psoriasis.org/about-psoriatic-arthritis. Accessed 5 Jun 2015.

Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med. 2017;376:957–70.CrossRefPubMed

Gan E, Chong W, Tey H. Therapeutic strategies in psoriasis patients with psoriatic arthritis: focus on new agents. BioDrugs. 2013;27:359–73.CrossRefPubMed

Menter A. Psoriasis and psoriatic arthritis treatment. Am J Manag Care. 2016;22:S225–37.PubMed

Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 6: Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions. J Am Acad Dermatol. 2011;65:137.CrossRefPubMed

Gottlieb A, Korman N, Gordon K, Feldman S, Lebwohl M, Koo JY, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol. 2008;58:851–64.CrossRefPubMed

Eder L, Thavaneswaran A, Chandran V, Cook R, Gladman DD. Factors explaining the discrepancy between physician and patient global assessment of joint and skin disease activity in psoriatic arthritis patients. Arthritis Care Res (Hoboken). 2015;67:264–72.CrossRef

Michelsen B, Kristianslund EK, Hammer HB, Fagerli KM, Lie E, Wierød A, et al. Discordance between tender and swollen joint count as well as patient's and evaluator's global assessment may reduce likelihood of remission in patients with rheumatoid arthritis and psoriatic arthritis: data from the prospective multicentre NOR-DMARD study. Ann Rheum Dis. 2017;76:708–11.CrossRefPubMed

10.

Desthieux C, Granger B, Balanescu AR, Balint P, Braun J, Canete JD, et al. Determinants of patient-physician discordance in global assessment in psoriatic arthritis: a multicenter European study. Arthritis Care Res (Hoboken). 2017;69:1606–11.CrossRefPubMed

11.

Lindström Egholm C, Krogh NS, Pincus T, Dreyer L, Ellingsen T, Glintborg B, et al. Discordance of global assessments by patient and physician is higher in female than in male patients regardless of the physician's sex: data on patients with rheumatoid arthritis, axial spondyloarthritis, and psoriatic arthritis from the DANBIO Registry. J Rheumatol. 2015;42:1781–5.CrossRefPubMed

12.

Kavanaugh A, Helliwell P, Ritchlin CT. Psoriatic arthritis and burden of disease: patients perspectives from the population-based multinational assessment of psoriasis and psoriatic arthritis (MAPP) survey. Rheumatol Ther. 2016;3:91–102.CrossRefPubMedPubMedCentral

13.

Flynn TN, Louviere JJ, Peters TJ, Coast J. Best-worst scaling: what it can do for health care research and how to do it. J Health Econ. 2007;26:171–89.CrossRefPubMed

14.

Louviere JJ, Flynn TN, Marley AAJ. Best-worst scaling: theory, methods, and applications. Cambridge: Cambridge University Press; 2015.CrossRef

15.

Nolla JM, Rodríguez M, Martin-Mola E, Raya E, Ibero I, Nocea G, et al. Patients’ and rheumatologists’ preferences for the attributes of biological agents used in the treatment of rheumatic diseases in Spain. Patient Prefer Adherence. 2016;10:1101–13. eCollection 2016PubMedPubMedCentral

16.

Umar N, Yamamoto S, Loerbroks A, Terris D. Elicitation and use of patients’ preferences in the treatment of psoriasis: a systematic review. Acta Derm Venereol. 2012;92:341–6.CrossRefPubMed

17.

Kauf TL, Yang JC, Kimball AB, Sundaram M, Bao Y, Okun M, et al. Psoriasis patients’ willingness to accept side-effect risks for improved treatment efficacy. Dermatolog Treat. 2015;26:507–13.CrossRef

18.

Hauber AB, Gonzalez JM, Schenkel B, Lofland J, Martin S. The value to patients of reducing lesion severity in plaque psoriasis. J Dermatolog Treat. 2011;22:266–75.CrossRefPubMed

19.

Basra MK, Fenech R, Gatt RM, Salek MS, Finlay AY. The Dermatology Life Quality Index 1994-2007: a comprehensive review of validation data and clinical results. Br J Dermatol. 2008;159:997–1035.PubMed

20.

Stamm TA, Nell V, Mathis M, Coenen M, Aletaha D, Cieza A, et al. Concepts important to patients with psoriatic arthritis are not adequately covered by standard measures of functioning. Arthritis Rheum. 2007;57:487–94.CrossRefPubMed

21.

Gossec L, de Wit M, Kiltz U, Braun J, Kalyoncu U, Scrivo R, et al. A patient-derived and patient-reported outcome measure for assessing psoriatic arthritis: elaboration and preliminary validation of the Psoriatic Arthritis Impact of Disease (PsAID) questionnaire, a 13-country EULAR initiative. Ann Rheum Dis. 2014;73:1012–9.CrossRefPubMed

22.

Gudu T, Etcheto A, de Wit M, Heiberg T, Maccarone M, Balanescu A, et al. Fatigue in psoriatic arthritis—a cross-sectional study of 246 patients from 13 countries. Joint Bone Spine. 2016;83:439–43.CrossRefPubMed

23.

Yuan Z, Levitan B, Burton P, Poulos C, Hauber AB, Berlin JA. Relative importance of benefits and risks associated with antithrombotic therapies for acute coronary syndrome: patient and physician perspectives. Curr Med Res Opin. 2014;30:1733–41.CrossRefPubMed

24.

Train K. Discrete choice methods with simulation. 1st ed. Cambridge: Cambridge University Press; 2003.CrossRef

25.

Train K, Sonnier G. Mixed logit with bounded distributions of correlated partworths. In: Scarpa R, Alberini A, editors. Applications of simulation methods in environmental and resource economics. Dordrecht: Springer Publisher; 2005. p. 117–34.

26.

Sawtooth Software, Inc. (2013). The MaxDiff/Web system technical paper. Provo: Sawtooth Software Technical Paper Series.

27.

Smolen JS, Braun J, Dougados M, Emery P, Fitzgerald O, Helliwell P, et al. Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Ann Rheum Dis. 2014;73:6–16.CrossRefPubMed

28.

Belinchón I, Rivera R, Blanch C, Comellas M, Lizán L. Adherence, satisfaction and preferences for treatment in patients with psoriasis in the European union: a systematic review of the literature. Patient Prefer Adherence. 2016;10:2357–67. eCollection 2016CrossRefPubMedPubMedCentral

29.

Zhang M, Brenneman SK, Carter CT, Essoi BL, Farahi K, Johnson MP, et al. Patient-reported treatment satisfaction and choice of dosing frequency with biologic treatment for moderate to severe plaque psoriasis. Patient Prefer Adherence. 2015;9:777–84.CrossRefPubMedPubMedCentral